Compare Alcon AG (ALC) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Schwab US Dividend Equity ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Schwab US Dividend Equity ETF trades at $32.36. The key difference: Alcon AG pays a 0.54% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | SCHD | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $92.22 | $32.83 |
52-Week Low | $62.02 | $26.38 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SCHD trades at $32.24, down 0.46% today, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's dividend strategy is gaining attention amid rising interest in income-focused investments, with recent articles highlighting its 3.29% yield and low 0.06% expense ratio. Support and resistance levels cluster around $32-$33, indicating potential consolidation near current levels.
SCHD offers exposure to quality dividend-paying US stocks but faces mixed sentiment with some analysts citing underperformance versus broader markets. The fund's defensive positioning provides income stability, though total return comparisons with growth-oriented ETFs remain a key consideration for investors seeking balanced portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
